0001209191-20-062624.txt : 20201209
0001209191-20-062624.hdr.sgml : 20201209
20201209195443
ACCESSION NUMBER: 0001209191-20-062624
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201207
FILED AS OF DATE: 20201209
DATE AS OF CHANGE: 20201209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rhodes Jason P
CENTRAL INDEX KEY: 0001577014
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 201379107
MAIL ADDRESS:
STREET 1: C/O EPIZYME, INC.
STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-07
0
0001737953
Replimune Group, Inc.
REPL
0001577014
Rhodes Jason P
18 COMMERCE WAY
WOBURN
MA
01801
1
0
0
0
Common Stock
2020-12-07
4
S
0
8636
45.46
D
2477660
I
See Footnote
Common Stock
2020-12-07
4
S
0
23174
45.97
D
2454486
I
See Footnote
Common Stock
2020-12-07
4
S
0
1222
46.91
D
2453264
I
See Footnote
Common Stock
2020-12-07
4
S
0
2962
45.45
D
1097038
I
See Footnote
Common Stock
2020-12-07
4
S
0
26713
46.06
D
1070325
I
See Footnote
Common Stock
2020-12-07
4
S
0
2322
46.93
D
1068003
I
See Footnote
Common Stock
2020-12-07
4
S
0
748
45.46
D
37822
I
See Footnote
Common Stock
2020-12-07
4
S
0
2007
45.97
D
35815
I
See Footnote
Common Stock
2020-12-07
4
S
0
106
46.91
D
35709
I
See Footnote
Common Stock
2020-12-08
4
S
0
7001
46.02
D
2446263
I
See Footnote
Common Stock
2020-12-08
4
S
0
33133
46.94
D
2413130
I
See Footnote
Common Stock
2020-12-08
4
S
0
19620
46.14
D
1048383
I
See Footnote
Common Stock
2020-12-08
4
S
0
45027
46.89
D
1003356
I
See Footnote
Common Stock
2020-12-08
4
S
0
606
46.02
D
35103
I
See Footnote
Common Stock
2020-12-08
4
S
0
2869
46.94
D
32234
I
See Footnote
Common Stock
2020-12-09
4
S
0
1745
42.51
D
2411385
I
See Footnote
Common Stock
2020-12-09
4
S
0
17883
43.36
D
2393502
I
See Footnote
Common Stock
2020-12-09
4
S
0
7330
44.69
D
2386172
I
See Footnote
Common Stock
2020-12-09
4
S
0
1747
45.32
D
2384425
I
See Footnote
Common Stock
2020-12-09
4
S
0
603
42.51
D
1002753
I
See Footnote
Common Stock
2020-12-09
4
S
0
6183
43.36
D
996570
I
See Footnote
Common Stock
2020-12-09
4
S
0
2535
44.69
D
994035
I
See Footnote
Common Stock
2020-12-09
4
S
0
604
45.32
D
993431
I
See Footnote
Common Stock
2020-12-09
4
S
0
100
46.47
D
993331
I
See Footnote
Common Stock
2020-12-09
4
S
0
151
42.51
D
32083
I
See Footnote
Common Stock
2020-12-09
4
S
0
1549
43.36
D
30534
I
See Footnote
Common Stock
2020-12-09
4
S
0
635
44.69
D
29899
I
See Footnote
Common Stock
2020-12-09
4
S
0
151
45.32
D
29748
I
See Footnote
Shares were sold pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.71 to
$45.708 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in
footnotes (2), (5), (6), (7), (9), (10), (12), (13), (14), (15), (16) and (17).
The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X") for no additional
consideration to its limited and general partner, Atlas Venture Associates X, L.P. ("AVA X LP") subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distributions
of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not
required to report these distributions pursuant to Section 16.
The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is AVA X LP. Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.71 to
$46.67 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.71 to
$47.19 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.71 to $45.70 inclusive.
The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.71 to $46.68 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.71 to $47.23 inclusive.
The shares are held directly by AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.52 to $46.42 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.55 to $47.45 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.95 to $42.91 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.97 to $43.94 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.06 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.07 to $45.96 inclusive.
/s/ Ommer Chohan, Attorney-in-Fact
2020-12-09